These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 26538627)

  • 1. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
    Seo GH; Cho YY; Chung JH; Kim SW
    Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
    Hisada M; Chen BE; Jaffe ES; Travis LB
    J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
    Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
    Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
    Lin CY; Lin CL; Huang WS; Kao CH
    J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
    Ahn HY; Min HS; Yeo Y; Ma SH; Hwang Y; An JH; Choi HS; Keam B; Im SA; Park DJ; Park IA; Noh DY; Youn YK; Chung JK; Cho BY; Park SK; Park YJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3486-93. PubMed ID: 26147607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
    Wu GX; Nelson RA; Kim JY; Raz DJ
    Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
    Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
    J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.
    Chaturvedi AK; Engels EA; Gilbert ES; Chen BE; Storm H; Lynch CF; Hall P; Langmark F; Pukkala E; Kaijser M; Andersson M; Fosså SD; Joensuu H; Boice JD; Kleinerman RA; Travis LB
    J Natl Cancer Inst; 2007 Nov; 99(21):1634-43. PubMed ID: 17971527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
    Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.